1

Introduction
The existence of cancer stem cells (CSC) was first demonstrated over a decade ago in acute myeloid leukemia (AML) using xenogeneic transplant models 1, 2 Thus, in a similar way to normal hematopoiesis, it was demonstrated that AML is arranged as a loose hierarchy in which a small population of self-renewing leukemic stem cells (LSC) give rise
to a large population of more mature leukemic blasts which lack self-renewal capacity.
This organization helps to explain the all too frequently observed clinical scenario in AML, whereby current chemotherapeutic regimens frequently induce remission but relapses, often fatal, are commonly observed. The hierarchical organization of AML suggests that this may relate to current therapeutics targeting only the rapidly proliferating leukemic progenitors, and not the more chemoresistant LSC 6 . A thorough understanding of how LSCs differ from their normal counterparts at both the phenotypic and molecular level is therefore pivotal to developing targeted therapies, with acceptable toxicities, for AML. This review will aim to describe recent advances in the LSC field with regard primarily to AML, although the concepts described will extend to LSC/CSC in other tumors. The cellular and molecular (both genetic and epigenetic)
properties of LSC, and how these might differ from normal hematopoietic stem cells (HSC), will be summarized and potential therapeutic targets explored.
Phenotypic characterisation of leukemic stem cells DOI: 10.3324/haematol.2011.054734 Initial studies suggested that LSC were restricted to the Lin -CD34 + CD38 -population, a phenotype shared by the HSC capable of reconstituting normal hematopoiesis in NOD/SCID mice 7 . However, since these initial studies, xenograft transplant models have been further refined through the administration of anti-CD122, to suppress Natural Killer cell function, as well as through the use of more immune deficient mouse strains such as NOD/SCID/β 2 m -/-or NOD/SCID/IL2Rγ -/-mice. Although these refinements did not facilitate engraftment of AML samples which failed to engraft in the original NOD/SCID model 8 , engraftment efficiency was increased in the newer models. Furthermore, they also allowed LSC activity to be demonstrated in the more mature Lin -CD34 + CD38 + progenitor population of some AML patients 9 . In addition, intra-femoral, rather than standard tail vein, injection of the transplanted cell innoculum was also found to increase the efficiency of disease transfer 10 . Using these refinements LSC were found in more than one compartment and the efficiency of disease transfer followed a hierarchy, with limiting dilution experiments demonstrating that the frequency of LSC was higher in the Lin -CD34 + CD38 -population compared to the Lin -CD34
+ CD38 + population. However, in both compartments LSC were rare and varied in frequency from 1 in 1.6 x10 3 to 1 in 1.1 x 10 6 cells 11 .
These studies suggest that the LSC compartment in AML is more heterogeneous than previously anticipated and includes cells with the surface phenotype of committed progenitors. Importantly, and granuloctye-monocyte progenitor (GMP) populations at both the phenotypic and molecular level 15 . Although the majority of AML cases express the CD34 marker, in some patients, including those with Nucleophosmin (NPM1) mutations, the CD34 + percentage is very low. In patients with <0.5% CD34 + cells, LSC activity was exclusively restricted to the CD34 -population, whereas in other patients LSC were present in both the CD34 + and CD34 -populations 16 . Together these studies confirm that the LSC population is phenotypically diverse and can vary markedly between patient sub-groups, and even between individual patients within these subgroups. However, how this might reflect the heterogeneity of the initial target cell transformed or the combinations of collaborating mutations is, as yet, unknown. (Figure 1) . A prerequisite for this argument is that, in the case of progenitor transformation, the initiating mutation must confer self-renewal activity to that compartment, in order for the mutation to be propagated.
Evolution of the leukemic stem cell compartment
The finding that multiple populations of LSC may exist within a single patient suggests that the LSC population is neither uniform nor static and may evolve from one cellular phenotype to another depending upon the acquisition of additional genetic or epigenetic alterations (Figure 2 ).
Genetic evolution of the LSC compartment has been most convincingly demonstrated in ALL.
The ETV6-RUNX1 translocation is a known initiating event that occurs prenatally in a subset of . Recent work, in which the genomes of AML patients at diagnosis and relapse were sequenced, has provided further insight into the clonal evolution of LSC during disease relapse. Additional mutations were acquired, in either the dominant clone at diagnosis or a minor sub-clone, which presumably enabled the cells to survive the selective pressures of chemotherapy and contribute to relapse 51 . This study demonstrates that elimination of not only the founding clone but also sub-clones derived from it are required for long-term remission and highlights the role that chemotherapy may play in contributing to disease relapse.
We have provided evidence that both the surface phenotype and mutational genotype of LSC can evolve with time, particularly under selective pressures such as chemotherapy. It has recently been demonstrated in solid organ tumors that altered epigenetic states may also provide sufficient survival/resistance signals for CSC to negotiate these "bottlenecks". In the first of these studies, the self-renewal of melanoma cells was demonstrated to be dependent upon dynamic, rather than hierarchical, regulation of the histone H3K4 demethylase JARID1B 52 . The . Taken together these findings suggest that in AML, altered epigenetic states play a role in mediating resistance of the LSC to chemotherapy.
Targeting the LSC compartment?
In order to effectively eradicate AML, drugs which selectively target the LSC compartment with minimum toxicity to the normal HSC compartment are required. Antigens which are selectively expressed by leukemic cells represent one such area of therapeutic intervention, and the use of Although this agent is effective at inducing remission in some patients, these patients are still prone to relapse, presumably because LSC are resistant to the toxin 61 . Moreover safety issues have been raised in at least one other trial and prolonged cytopenias have also been described Several antigens are more highly expressed by AML LSC than normal HSC. This raises the possibility of a 'therapeutic window' whereby therapeutic antibodies could be used to selectively target LSC whilst sparing HSC (see Table 1 ). Indeed, promising results were obtained when some of these antigens were targeted in xenografts. Importantly, in all cases LSC were selectively targeted by the treatment and HSC were significantly less affected.
An alternative strategy is to target the initiating mutation or molecular pathways directly downstream. As direct proof of principle for this concept, several studies have ablated the initiating mutation in murine models of leukemia, leading to their regression. For example, the MLL-ENL fusion protein is sufficient for both the initiation and maintenance of disease in mouse models 64, 65 . Ablation of MLL-ENL expression in mice with established AML resulted in disease regression, despite the acquisition of additional mutations 65 . Thus, despite evolution of the disease, the leukemic cells remained addicted to the initiating oncogenic lesion, indicating that therapies which interfere with MLL-fusion protein activity would be of therapeutic benefit.
MLL-fusion proteins aberrantly regulate gene expression through a number of interactions with multi-protein complexes including members of the super elongation complex (SEC) 66, 67 and polymerase-associated factor complex (PAFc) 68, 69 . These associations are mediated, at least in part, through interaction with the bromodomain and extra-terminal (BET) chromatin adaptor In summary, it is apparent that the vast heterogeneity evident in AML extends to the LSC compartment at both the cellular and molecular level. However, our knowledge base for LSC biology and how this might differ from HSC biology continues to grow. The further identification of new LSC-specific markers represents a novel therapeutic avenue, although it is becoming apparent that no single marker is uniform for LSC between, and even within, individual patients. In addition, mouse models will continue to be invaluable tools for the study of mechanisms of leukemic transformation, LSC biology and therapy. Gene expression profiles of LSC enriched populations have also begun to provide much needed knowledge about the molecular mechanisms mediating self-renewal of human LSCs. However, the limited overlap in expression signatures between pioneering studies requires further scrutiny. Finally, proof-ofprinciple studies demonstrate that initiating lesions may be targeted, even those which require
inhibition of a protein-protein interaction. Therefore, although targeted patient-specific therapies might still be a considerable way off for the majority of patients, therapies which target specific initiating mutations, their downstream pathways and LSC selective surface antigens are now a reality and clinical trials are underway for these as single agents. However, their long-term place in the treatment of AML will no doubt require their combination with standard chemotherapeutics. These studies are eagerly awaited and will hopefully yield exciting results. 
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L a n c e t . 1 9 9 9 ; 3 5 4 ( 9 1 8 9 ) : 1 4 9 9 -5 0 3 . Alternatively mutations may occur in the aforementioned progenitor populations. However, since these cells inherently lack self-renewal activity, the mutation must confer this capacity to the progenitors in order for the mutation to be propagated in a self-renewing (pre)-LSC. ENL activity is a potential therapeutic approach. It is likely that targeting the subsequent driver mutations will also abrogate leukemia growth, although the tumours may be less dependent upon these lesions than initiating mutations. In addition, targeting pathways downstream of the initiating lesion such as Hoxa9, Meis1 and Myb is also a valid strategy. An alternate, and not mutually exclusive, strategy would be to target aberrant LSC-selective surface markers with antibodies or antibody conjugates. In reality, it is likely that such targeted therapies would need to be combined with each other and current chemotherapies for maximal effect, but it is hoped that efficient targeting of the LSC compartment should result in either loss of self-renewal, apoptosis or differentiation leading to improved outcomes in patients with AML.
